cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Yolanda Handayani
Contact Email
yola.aksel@gmail.com
Phone
+6282157048069
Journal Mail Official
respirologyscience@gmail.com
Editorial Address
Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Location
Kota adm. jakarta timur,
Dki jakarta
INDONESIA
Respiratory Science
Published by Perhimpunan Dokter Paru Indonesia
ISSN : -     EISSN : 27471306     DOI : https://doi.org/10.36497/respirsci.v1i3.17
Core Subject : Health,
Health Professions Medicine & Pharmacology
Focuses on original article reviews and case reports in pulmonary and critical care medicine Scope: 1. Asthma 2. Chronic Obstructive Pulmonary Disease (COPD) 3. Lung Physiology and Sleep-Related Disorder 4. Lung Infection 5. Thoracic Oncology 6. Interstitial Lung Disease 7. Environmental Lung Disease 8. Tobacco Control 9. Occupational Pulmonary Disease 10. Pulmonary Intervention and Emergency Medicine 11. Respiratory critical care 12. Respiratory immunology and biomolecular
Arjuna Subject : Kedokteran - Kedokteran Paru dan Pernafasan
Articles 6 Documents
 1 
Search results for , issue "Vol. 3 No. 3 (2023): Respiratory Science" : 6 Documents clear
Inflammatory Markers of ARDS Events among Patients with Severe and Critical COVID-19 Infection at Adam Malik General Hospital, Medan, North Sumatera Eva Susanti Debora Hutabarat; Fajrinur Syarani; Syamsul Bihar; Putri Chairani Eyanoer
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.78

Abstract

Background: COVID-19 can cause fatal outcomes, especially acute respiratory distress syndrome (ARDS). It manifests as organ dysfunction during COVID-19's hyperinflammatory phase, which is associated with a high mortality rate. Data on the clinical characteristics and inflammation markers of patients with severe and critical degrees of COVID-19 with ARDS events are limited. Method: This study is carried out at the Haji Adam Malik General Hospital in Medan. We grouped 204 medical records from February to July 2022 of hospitalized patients with severe and critical COVID-19 cases into two groups, ARDS and non-ARDS. Characteristics of demographic and laboratory inflammatory markers upon admission between each group were collected. After collecting data and serving as categorical data in the frequency distribution table by SPSS ver 25.0. Results: We identified 116 patients (56.9%) who had ARDS event upon hospital admission. ARDS event are most commonly found in the elderly group and the median age of ARDS group patients was 59.5 years higher than the non-ARDS group. Male patients were more likely to have ARDS than female patients. Compared with the non-ARDS group, ARDS group patients had lymphocytopenia, neutrophilia, increased neutrophil-to-lymphocyte ratio (NLR), Procalcitonin and C-Reactive Protein levels. Conclusion: Lymphocytopenia, neutrophilia, increased NLR, procalcitonin and CRP levels upon admission revealed that they were higher in ARDS patients compared to non-ARDS patients. It is critical to identify high-risk groups, such as male sex, the elderly, those with comorbidities, and patients with impaired inflammatory markers to prevent severe complications from COVID-19.
Dust Exposure and Lung Function Disorders Mona Lestari; Poppy Fujianti; Novrikasari Novrikasari; Rizka Faliria Nandini
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.80

Abstract

Dust is a particle floating in the air produced due to mechanical processes such as splitting, grinding, grinding, punching or blasting, cutting and destroying material. Dust particles in the air for a relatively long time can enter the human body through breathing. Dust less than 5 µm entering the human respiratory system can reach the inside of the lungs or alveoli can cause lung function disorders. Impaired pulmonary function is the inability to develop (elasticity) of the lungs as well as disorders of the respiratory tract both structural (anatomical) and functional which causes slowing of respiratory airflow. The International Labor Organization (ILO) defines pulmonary dysfunction as the accumulation of dust in the lung tissue and lung tissue reaction to the dust accumulation. Dust entering the alveoli can cause hardening of the tissue (fibrosis) and if 10% of the alveoli is hardening, it will reduce its elasticity in accommodating the volume of air so that the ability to bind oxygen is decreased. This condition causes a reduction in the supply of oxygen absorbed by blood capillaries to the brain tissue, heart, and other body parts.
Vancomycin-Allergy and Linezolid-Resistance in Patient with Methicillin-Resistance Staphylococcus aureus and Multi-Drug Resistance Acinetobacter baumannii Infection Wahyu Semara Putra Wayan; Dwita Yaniswara Ni Made; Sandy Laveda; Evelyn Nathania
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.82

Abstract

Background: Hospital Acquired Pneumonia (HAP) has been burdening the healthcare system, especially when bacteria such as Acinetobacter baumannii and methicillin-resistance Staphylococcus aureus (MRSA) are involved. They created a dilemma regarding the appropriate antibiotic therapy utilized against them, especially when the patient is allergic/intolerant to their drug of choice. Case: A 71-year-old man developed HAP while he was admitted for an ischaemic stroke. His bronchoalveolar lavage (BAL) culture showed MRSA and Acinetobacter baumannii infection with multiple drug resistance including one of the drugs for MRSA infection, linezolid. Amikacin and vancomycin were given, but he developed an allergy to vancomycin. Due to the difficulty in treating him, we opted to administer only amikacin. His clinical condition showed daily improvement. During the last day of hospitalization, his sputum culture showed only normal flora. He no longer needed oxygen therapy and there was no longer any indication for him to be hospitalized. Conclusion: Individuals with multiple comorbidities, recent antibiotic use within the past 90 days, and immune-deficient conditions are at a higher risk of developing infections, including the possibility of dual infections. In this case, we found that the patient was unable to tolerate first-line drugs for MRSA like linezolid and vancomycin, which makes it difficult to decide upon effective treatments.
Analysis of C-Reactive Protein, Neutrophil-to-Lymphocyte Ratio, PaO2/FiO2 Ratio on the Success of High Flow Nasal Cannula Usage in Hospitalized COVID-19 Patients Arina Aftritia Izzati; Ungky Agus Setyawan; Rezki Tantular
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.85

Abstract

Background: Several studies had shown High Flow Nasal Cannula (HFNC) is effective in treating hypoxemic COVID-19 patients. The C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio is an inflammatory marker that could predict the severity of COVID-19, where the P/F ratio infers oxygenation status. Since COVID-19-related ARDS is closely related to a hyper-inflammatory state and HFNC becomes widely utilized for hypoxemic patients, it has become important to discover reliable inflammatory biomarkers related to therapeutic HFNC success. This study aims to assess the factors that influence the success of HNFC therapy, in terms of demographic and laboratory profiles of CRP, NLR, and P/F ratio. Method: A retrospective, single-center cohort study was conducted in a tertiary care hospital in Malang, East Java from January to March 2022. Subjects of 31 PCR-confirmed, hospitalized COVID-19 patients who were treated with HFNC were included. Results: This study involved 2 groups comprised of 19 subjects with successful HFNC and 12 patients who failed. Significant demographic factors affecting successful HFNC were female gender (OR=1.46 95% CI=1.08-1.99; P=0.037) and occupation type (P=0.023). Whereas, biomarkers of CRP (8.90±6.8 mg/L vs 12.39±11.7 mg/L; P=0.656), NLR (7.24±4.66 vs 12.85±12.9; P=0.243) and P/F ratio (171.40±54 vs 148.00±40; P=0.219) were found to be non-significant between successful and failed HFNC cohorts, respectively. Conclusion: HFNC could provide a specific positive end-expiratory pressure in COVID-19 patients with contributing factors of successful HFNC being female and occupational type. However, CRP, NLR, and P/F did not contribute significantly to HFNC's success.
Mycobacterium tuberculosis Involvement in Tetralogy of Fallot: A Case Report of Tetralogy of Fallot Patient with Pulmonary Tuberculosis in A Tertiary Health Care in Indonesia Harik Firman Thahadian; Sumardi Sumardi; Eko Budiono
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.87

Abstract

ckground: Pulmonary tuberculosis in patients with congenital heart disease is a rare case and remains challenging to diagnose and treat. This study aimed to emphasize the association between pulmonary tuberculosis infection and management in patients with congenital heart disease. Case: This case study presents 18-year-old male with Tetralogy of Fallot (ToF) who had pulmonary tuberculosis. The tuberculosis diagnosis was confirmed clinically, followed by positive IGRA. The patient underwent standard care within the hospital and upon discharge, he was prescribed with standard anti-tuberculosis regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol (RHZE) for a week then discontinued it. After 3 months the patient initiated intensive phase (RHZE) for 2 months and followed by 4-month maintenance phase of Isoniazid and Rifampicin. Immediate evaluation showed improved patient’s chest radiography and symptoms’ remission. This study presented provisioning therapy regimen and nutritional care delivery for pulmonary tuberculosis patient with ToF. Further patient’s clinical evaluation suggested a substantial recovery process. The patient prescribed with infection control and dietary management upon hospital discharge. Counseling to improve patient’s knowledge was performed to prevent recurrent TB. Collaborative care established between internal medicine specialists, cardiologist, pulmonologist, and clinical nutritionist appeared to be effective to promote patient’s recovery and quality of life (QoL). Conclusion: Appropriate management of cases improves patient outcomes and QoL. Early screening, diagnosis and treatment should be introduced regardless of the patient’s clinical status. Adequate support from the patient’s family and relatives are required to eliminate TB infection.
Myocard Injury in COVID-19 Patients After Application Of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) as Adjuvant Therapy in Persahabatan Hospital Mega Juliana; Triya Damayanti; Yasmina Hanifah; Erlina Burhan
Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v3i3.89

Abstract

Background: Myocardial injury was a frequent cardiovascular manifestation of COVID-19 and associated with high mortality.  Cell-based approaches, primarily using mesenchymal stem cell (MSC) has demonstrated safety and possible efficacy as adjuvant therapy in COVID-19 patients. This study aims to evaluate myocardial injury in patients with moderate-severe and critically ill COVID-19 after the application of umbilical cord mesenchymal stem cell (UC-MSC) as adjuvant therapy in Persahabatan hospital. Method: This is a retrospective and prospective cohort study. A total of 28 subjects were allocated to 13 subjects in the control and 15 subjects in the experimental group. Subjects were given the standard treatment and UC-MSC or placebo. Myocardial injury is defined by an increase of troponin I >26 pg/ml. The biomarkers of troponin I, NT-proBNP and CRP was examined periodically. Cardiac pump evaluated by EF and TAPSE from echocardiography examination before and after UC-MSC application. The evaluation of myocardial injury, biomarkers, cardiac pump and 15-day mortality were observed between the two groups. Results: The incidence of myocardial injury was 28,6% of total subjects. Subjects with worsening myocardial injury were higher in the control group (6 subjects) than the experimental group (4 subjects) although not statistically significant. The difference in biomarkers (troponin I, NT- pro-BNP and CRP), cardiac pump function (EF and TAPSE) and 15-day mortality between two groups were not statistically significant. There was a trend of decreasing troponin I, NT-proBNP and CRP in the experimental group. Conclusion: UC-MSC application can be an option as adjuvant therapy in improving myocardial injury of moderate-severe and critically ill COVID-19 patients.

Page 1 of 1 | Total Record : 6

 1 

Filter by Year

2023 2023


Reset
Filter By Issues
All Issue Vol. 6 No. 1 (2025): Respiratory Science Vol. 5 No. 3 (2025): Respiratory Science Vol. 5 No. 2 (2025): Respiratory Science Vol. 5 No. 1 (2024): Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science Vol. 4 No. 2 (2024): Respiratory Science Vol. 4 No. 1 (2023): Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science Vol. 3 No. 2 (2023): Respiratory Science Vol. 3 No. 1 (2022): Respiratory Science Vol. 2 No. 3 (2022): Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science Vol. 2 No. 1 (2021): Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science Vol. 1 No. 2 (2021): Respiratory Science Vol. 1 No. 1 (2020): Respiratory Science More Issue